International Women’s Day 2021: Q&A with Kate Bache, co-founder & managing director of Health and Her

No items found.
​
March 8, 2021

This year, the International Women’s Day theme is ‘choose to challenge’ with a focus on challenging change to create a gender equal world.

The day marks a call to action for accelerating women’s equality, celebrating women’s achievements and raising awareness against bias. Throughout the year, we have observed EIP clients who are committed to improving gender equality and today we are celebrating them.

About Health & Her®

Health & Her® is an award-winning health hub that aims to cut through the confusion when it comes to female health. Health & Her provides advice and support from the UK’s leading menopause experts via their expert articles and Menopause Clinic. They offer a range of the best products from around the world to support perimenopause and menopause symptoms and a free ‘personal trainer’ app designed to coach women through menopause.

Health & Her are on a mission to improve lives of millions of women around the world living with life-affecting symptoms of menopause.

Meet Kate Bache

Originally a qualified chemist (MChem), Kate quickly moved into commercial roles and has more than 13 years’ experience in blue chip pharmaceutical and FMCG companies.

Kate has held senior marketing and innovation positions in international functions across Europe and Australasia for Reckitt Benckiser, Kellogg’s and PepsiCo. A specialist in international innovation, commercialisation and marketing leadership, Kate initially started her entrepreneurial endeavours by founding and successfully exiting successful femcare brand, KIND Organic.

It was during this time, Kate discovered the complete lack of support for women experiencing severe symptoms of female health and in particular the poor availability of products and solutions for women experiencing menopause.

Hi Kate. Could you tell us more about what made you want to start Health and Her?

My initial research unearthed some shocking statistics related to this stage of women’s lives with the highest rates of divorce, suicide and job leavers associated with women aged 45-55. Further studies conducted by Health & Her showed the far-reaching impact of these issues with the UK economy losing 14 million days a year[1] to women managing symptoms associated with menopause. This equates to £1.8bn GDP lost annually.

There was a clear gap in the market for a resource where women could understand their choices, discover information and find solutions and so Health & Her was born.

Where do you see the femtech industry being in five years’ time?

Femtech is an incredibly exciting industry at the moment with very high levels of innovation that are directly impacting on women’s lives. For me, the most exciting direction of travel is towards highly personalised solutions based on an individual’s hormones. I believe that in 5 years’ time, we could see ideas which would significantly improve women’s female health symptoms through passive diagnostic and delivery technology.

How has the growing discussion about women's health affected your business?

Menopause in particular has become a hot topic in recent years and this has certainly allowed us to talk more directly to women about their options. There’s still a long way to go vs. other women’s health issues such as periods and fertility but as these younger generations start to move toward perimenopause, we hope that their openness to these subjects will translate into menopause and the topic gets the airtime it needs to improve the lives of millions of women.

How can everyone get involved in supporting smarter women’s health?

This International Women's day we want to #ChooseToChallenge the taboos around Menopause and open the conversation for us all to talk about the symptoms of perimenopause and menopause and how they impact the millions of women in the UK.

Women’s health doesn’t just affect women. Fathers, brothers, husbands, sons and society as a whole are affected by the challenges of female health. We have an incredibly long way to go to solve the issues that millions of women face every day and I believe that we need everyone to realise this to make significant and lasting change for the better.

[1] Censuswide survey, 1003 menopausal women, UK, 2019

At EIP, we are committed to diversity and inclusion. We believe in equal opportunity in all areas and we are proud that diversity is a core part of our culture.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Quantum IP Strategy: Own control Points, Not Patent Counts
14 October 2026
In quantum, the strongest portfolios will not be the biggest. Stuart Malcolm sets out six moves for owning the control points the market cannot route around, and the questions investors will ask.
#
Consulting
​
Targeted, Not Transformative: The UKIPO’s Considered Course on SEPs
13 October 2026
Andrew Sharples analyses the UKIPO's response to its SEP consultation, exploring proposed changes to FRAND dispute resolution, SEP transparency and licensing guidance, and what they mean for SEP holders and implementers.
#
Consulting
​
Chinese Companies in European Patent Litigation
30 September 2026
Chinese companies are becoming increasingly active in European patent litigation, both as defendants and as patent owners enforcing their own rights. This article examines the growing role of Europe and the Unified Patent Court (UPC) in global patent disputes, highlighting key cases involving Chinese businesses and the strategic opportunities and risks that come with operating in European markets. It is the first in a series exploring the practical implications of European patent enforcement for Chinese companies.
#
Patenting
​
How to mitigate prior art traps for follow-on pharma patents
27 August 2026
Follow-on patents are increasingly important for pharmaceutical innovators. Learn how new EMA clinical trial disclosure rules create prior art risks and discover practical strategies to protect pharmaceutical IP and maximise patent value.
#
Consulting
​
Chinese companies and the UPC: from enforcement targets to strategic users
13 August 2026
Chinese companies are playing an increasingly significant role in UPC litigation, accounting for around 38% of infringement actions in 2025. While many remain defendants, a growing number are actively using the Unified Patent Court to enforce their own patent rights across Europe. The trend highlights the UPC's rising importance for Chinese businesses operating in sectors such as telecommunications, semiconductors, medical devices and renewable energy, and signals a shift in global patent enforcement strategy.
#
Patenting
​
Evaluating the environmental impact of patent AI.
31 July 2026
AI's environmental impact is rarely out of the headlines, but how does it compare to the benefits it delivers in practice? In this article, Laurence Brown examines the energy use of AI-assisted patent drafting, comparing it with traditional drafting workflows. While measuring AI's true environmental footprint is far from straightforward, the analysis suggests that AI-assisted patent drafting may already be more energy efficient, while delivering significant productivity gains for patent professionals.
#
Patenting
​
UPC appeals after three years: Early indications on appeal success rates
15 July 2026
Three years into the UPC, appeal overturn rates sit at 56% for both substantive and preliminary injunction cases, with Kodak v Fujifilm among the rulings reshaping outcomes on appeal.
#
Litigation
​
The UPC After Three Years: From Experiment to Enforcement Forum
15 July 2026
1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.
#
Litigation
​
Podcast: Building an AI-Native Law Firm
26 June 2026
On the Technically Legal podcast, EIP partner Laurence Brown discusses how Visser AI is redesigning patent workflows, letting the firm offer fixed fees without trading away speed or quality.
#
Patenting
​
Choosing your SEP battleground: UPC, Germany or UK?
07 June 2026
Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.
#
Litigation
​
Synthetic Lethality & AI: IP Strategy in Oncology
26 May 2026
This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.
#
Consulting
​
Inside the Visser AI Launch Party
20 May 2026
EIP has officially launched Visser AI®, our hybrid intelligence service for patent drafting and prosecution. Watch the launch film from our event at The Boundary in Shoreditch, and discover how our team of European and US patent attorneys — working with the Patently AI platform , delivers faster, lower-cost work at the EPO, USPTO and beyond.
#
Consulting
​
Protecting Your Startup: Five Intellectual Property Mistakes to Avoid
20 May 2026
Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.
#
Consulting
​
Technology, Patents, and Sport
13 May 2026
VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.
#
Patenting
​
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
#
Patenting
​